Digital Biopharmaceuticals / AI-Enabled Drug Discovery
Strategic Profile
Bullfrog AI delivers AI solutions including its bfLEAP® platform (originally developed at Johns Hopkins Applied Physics Lab) that analyzes complex biomedical data to uncover patterns, paired with bfPREP™ for data standardization. The company has a collaboration with Sygnature Discovery expected to generate $15–$30 million revenue through 2028.
Cyborg Score Rationale
Bullfrog AI has promising AI/ML technology and strategic partnerships with academic institutions and pharma CROs. However, the company is pre-revenue dependent with high negative earnings and a micro-cap valuation of $6.7M. Stock performance has declined 59.69% over the past year with an all-time high of $9.50 in April 2023.
Top Insights
Pre-revenue or early-revenue model with commercial partnerships in early stages (Sygnature Discovery projected $15-30M through 2028)
Access to world's largest human brain data repository via Lieber Institute partnership provides competitive moat in neuropsychiatric drug discovery
Minimal headcount (9 employees as of Jan 2026) enables capital-efficient scaling but limits operational capacity
Multiple early-stage drug candidates in development (BF-222, BF-223, BF-114, Modified HSV-1) alongside platform revenue opportunities
Named Competitors
AI-Driven Drug Discovery Platforms — Computational drug discovery and development platform
Clinical Data Analytics — AI-powered clinical and genomic data analysis
Pharma Services — Computational solutions for drug development
Recent Developments
(June 2025) Continued pharma partnership discussions for drug target discovery
(December 2024) Company announcements regarding AI-driven drug discovery initiatives
(August 2024) Leadership announcements in AI-driven drug discovery sector
Open the full interactive Bullfrog AI Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.